Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa

Joana C. Silva, Ankit Dwivedi, Kara A. Moser, Mahamadou S. Sissoko, Judith E. Epstein, Sara A. Healy, Kirsten E. Lyke, Benjamin Mordmüller, Peter G. Kremsner, Patrick E. Duffy, Tooba Murshedkar, B. Kim Lee Sim, Thomas L. Richie and Stephen L. Hoffman ()
Additional contact information
Joana C. Silva: University of Maryland School of Medicine
Ankit Dwivedi: University of Maryland School of Medicine
Kara A. Moser: University of Maryland School of Medicine
Mahamadou S. Sissoko: University of Science, Techniques and Technologies of Bamako
Judith E. Epstein: Naval Medical Research Center
Sara A. Healy: Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH
Kirsten E. Lyke: Center for Vaccine Development and Global Health, University of Maryland School of Medicine
Benjamin Mordmüller: University of Tübingen and German Center for Infection Research
Peter G. Kremsner: University of Tübingen and German Center for Infection Research
Patrick E. Duffy: Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH
Tooba Murshedkar: Sanaria Inc.
B. Kim Lee Sim: Sanaria Inc.
Thomas L. Richie: Sanaria Inc.
Stephen L. Hoffman: Sanaria Inc.

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract Controlled human malaria infection (CHMI) has supported Plasmodium falciparum (Pf) malaria vaccine development by providing preliminary estimates of vaccine efficacy (VE). Because CHMIs generally use Pf strains similar to vaccine strains, VE against antigenically heterogeneous Pf in the field has been required to establish VE. We increased the stringency of CHMI by selecting a Brazilian isolate, Pf7G8, which is genetically distant from the West African parasite (PfNF54) in our PfSPZ vaccines. Using two regimens to identically immunize US and Malian adults, VE over 24 weeks in the field was as good as or better than VE against CHMI at 24 weeks in the US. To explain this finding, here we quantify differences in the genome, proteome, and predicted CD8 T cell epitopes of PfNF54 relative to 704 Pf isolates from Africa and Pf7G8. We show that Pf7G8 is more distant from PfNF54 than any African isolates tested. We propose VE against Pf7G8 CHMI for providing pivotal data for malaria vaccine licensure for travelers to Africa, and potentially for endemic populations, because the genetic distance of Pf7G8 from the Pf vaccine strain makes it a stringent surrogate for Pf parasites in Africa.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30882-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30882-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30882-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().